OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).

[1]  M. Banach,et al.  Lipid-lowering therapies: Better together. , 2021, Atherosclerosis.

[2]  M. Banach,et al.  Drucebo effect – the challenge we should all definitely face! , 2021, Archives of medical science : AMS.

[3]  M. Banach,et al.  How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. , 2020, Progress in cardiovascular diseases.

[4]  E. Hagström,et al.  Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study , 2020, European heart journal.

[5]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[6]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[7]  D. Gaudet,et al.  Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. , 2020, European journal of preventive cardiology.

[8]  M. Banach,et al.  Statins and LDL-C in Secondary Prevention-So Much Progress, So Far to Go. , 2020, JAMA network open.

[9]  M. Banach,et al.  LDL-C: lower is better for longer—even at low risk , 2020, BMC Medicine.

[10]  Ž. Reiner.  Why might visit-to visit variability of lipoproteins have an effect on cardiovascular events? , 2020, Atherosclerosis.

[11]  A. Parkhomenko,et al.  EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. , 2020, European journal of preventive cardiology.

[12]  Deepak L. Bhatt,et al.  Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. , 2020, European journal of preventive cardiology.

[13]  P. Vardas,et al.  Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project. , 2020, European heart journal.

[14]  J. Jozwiak,et al.  2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders , 2020, Archives of medical science : AMS.

[15]  R. Krauss,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel , 2020, European heart journal.

[16]  Panos Vardas,et al.  European Society of Cardiology: Cardiovascular Disease Statistics 2019. , 2019, European heart journal.

[17]  M. Banach,et al.  Inclisiran-New hope in the management of lipid disorders? , 2019, Journal of clinical lipidology.

[18]  M. Banach,et al.  P3400Definition of extremely high cardiovascular risk in patients after acute myocardial infarction - Data from the TERCET Registry , 2019, European Heart Journal.

[19]  J. Jozwiak,et al.  P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel , 2019, European Heart Journal.

[20]  Laney K. Jones,et al.  Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. , 2019, Journal of clinical lipidology.

[21]  K. Szydło,et al.  Managed Care after Acute Myocardial Infarction (KOS-zawał) reduces major adverse cardiovascular events by 45% in 3-month follow-up – single-center results of Poland’s National Health Fund program of comprehensive post-myocardial infarction care , 2019, Archives of medical science : AMS.

[22]  J. De Sutter,et al.  Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. , 2019, Atherosclerosis.

[23]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[24]  P. Jankowski,et al.  Comprehensive coordinated care after myocardial infarction (KOS‑Zawał): a patient's perspective. , 2019, Kardiologia polska.

[25]  M. Banach,et al.  What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? , 2019, Cardiovascular research.

[26]  M. Banach,et al.  Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions , 2018, Journal of cachexia, sarcopenia and muscle.

[27]  M. Banach,et al.  Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? , 2018, Expert opinion on pharmacotherapy.

[28]  D. Mikhailidis,et al.  Statin loading in cardiovascular surgery: never too early to treat , 2018, Current opinion in cardiology.

[29]  D. Davis.  Statin Denial: An Internet-Driven Cult With Deadly Consequences , 2018, Annals of Internal Medicine.

[30]  K. Poh,et al.  Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. , 2017, Atherosclerosis.

[31]  L. Räber,et al.  Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes , 2017, Journal of the American Heart Association.

[32]  S. Nissen.  Statin Denial: An Internet-Driven Cult With Deadly Consequences , 2017, Annals of Internal Medicine.

[33]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[34]  M. Banach,et al.  Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[35]  M. Banach,et al.  Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. , 2016, International journal of cardiology.

[36]  Jennifer G. Robinson,et al.  Determining When to Add Nonstatin Therapy: A Quantitative Approach. , 2016, Journal of the American College of Cardiology.

[37]  J. Spertus,et al.  Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction. , 2016, JAMA cardiology.

[38]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[39]  M. Banach,et al.  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.

[40]  W. Aronow,et al.  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Archives of medical science : AMS.

[41]  Ž. Reiner,et al.  Adverse effects of statins - myths and reality. , 2015, Current pharmaceutical design.

[42]  Ž. Reiner.  Resistance and intolerance to statins. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[43]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[44]  G. Boysen.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[45]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[46]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[47]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[48]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[49]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.